Details of the Drug Combination

General Information of Drug Combination (ID: DCKSI5R)

Drug Combination Name
Brilinta Eptifibatide
Indication
Disease Entry Status REF
Acute Coronary Syndrome Phase 2 [1]
Component Drugs Brilinta   DMBR01X Eptifibatide   DMQXTJS
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Brilinta
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [2]
Thrombosis DB61-GB90 Approved [3]
Arterial thrombosis DB61-DD30 Phase 3 [4]
Myocardial infarction BA41-BA43 Phase 3 [4]
Peripheral vascular disease BD4Z Investigative [5]
Brilinta Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
P2Y purinoceptor 12 (P2RY12) TTZ1DT0 P2Y12_HUMAN Antagonist [9]
------------------------------------------------------------------------------------
Brilinta Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]
------------------------------------------------------------------------------------
Brilinta Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [11]
------------------------------------------------------------------------------------
Brilinta Interacts with 8 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Terminal nucleotidyltransferase 4A (TENT4A) OT0G3KR0 PAPD7_HUMAN Increases ADR [12]
CD9 antigen (CD9) OT2184XU CD9_HUMAN Increases ADR [12]
Ephrin type-A receptor 4 (EPHA4) OT3AMK0C EPHA4_HUMAN Increases ADR [12]
Aryl-hydrocarbon-interacting protein-like 1 (AIPL1) OT4VBD78 AIPL1_HUMAN Increases ADR [13]
Actin-related protein 2/3 complex subunit 1A (ARPC1A) OTAEEXGQ ARC1A_HUMAN Increases ADR [8]
Putative protein CASTOR3P (GATS) OTDYE3XK CAST3_HUMAN Increases ADR [8]
LIM domain kinase 2 (LIMK2) OTRJD7VZ LIMK2_HUMAN Increases ADR [12]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Increases ADR [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DOT(s)
Indication(s) of Eptifibatide
Disease Entry ICD 11 Status REF
Acute cardiac ischemic events BA40.Z Approved [6]
Acute coronary syndrome BA41 Approved [7]
Pneumonia CA40 Approved [7]
Eptifibatide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) TT38RM1 ITA2B_HUMAN; ITB3_HUMAN Modulator [14]
------------------------------------------------------------------------------------
Eptifibatide Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Prothrombin (F2) OTNFSM49 THRB_HUMAN Increases Expression [15]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Increases Expression [15]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [15]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [15]
Integrin alpha-IIb (ITGA2B) OT4Y17PY ITA2B_HUMAN Increases ADR [16]
Integrin beta-3 (ITGB3) OTWCK1K6 ITB3_HUMAN Increases ADR [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 ClinicalTrials.gov (NCT01919723) Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion
2 Ticagrelor-Induced Syncope/Bradyarrhythmia. Cureus. 2021 Jan 23;13(1):e12874.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1765).
4 ClinicalTrials.gov (NCT01732822) A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease. U.S. National Institutes of Health.
5 Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. Drugs. 2022 Aug;82(12):1287-1302.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6585).
7 Eptifibatide FDA Label
8 Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015 Aug 1;36(29):1901-12.
9 Clinical pipeline report, company report or official report of AstraZeneca (2009).
10 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
11 Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21.
12 Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet. 2013 Sep;50(9):599-605. doi: 10.1136/jmedgenet-2012-101466. Epub 2013 Jun 17.
13 Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clin Cancer Res. 2015 Oct 1;21(19):4337-46. doi: 10.1158/1078-0432.CCR-15-0133. Epub 2015 May 26.
14 Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62.
15 Eptifibatide in peripheral vascular interventions: results of the Integrilin Reduces Inflammation in Peripheral Vascular Interventions (INFLAME) trial. J Invasive Cardiol. 2006 Jan;18(1):6-12.
16 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.